{'fraction_non_alphanumeric': 0.02176541717049577, 'fraction_numerical': 0.0024183796856106408, 'mean_word_length': 5.8429752066115705, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
EVALUATION OF SARCOPENIA IN PATIENTS WITH ACUTE KIDNEY INJURY: USE OF SERUM BIOMARKERS

Sarcopenia is a syndrome characterized by progressive loss of skeletal muscle mass, decreased strength, decreased physical performance, increased risk of falls, fractures, hospitalization, and mortality. In patients with chronic renal disease on dialysis (CKD) approximately 40% present sarcopenia due to the effect of toxic substances that are not excreted and induce activation of the inflammatory response that contributes to muscle catabolism, mitochondrial alterations, decrease of satellite cells, changes hormones and loss of neuromuscular junctions. Sarcopenia is well documented in patients with CKD, where the diagnosis is made by measuring the skeletal muscle index, measuring the strength of the wrist and low speed in walking.